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Dear Editor, 20 
Fortún and colleagues, in this Journal, compared candidaemias in two 5-year periods (2000-21 
2004 and 2005-2009) in a single institution.1 They observed a significant increase in the 22 
number of cases per 1000 admissions per year between study periods: in the first period, 23 
Candida albicans was the most frequently isolated species (42%), followed by Candida 24 
parapsilosis (34%) and Candida glabrata (13%). In the second period, episodes were 25 
associated with higher comorbidity and were more commonly nosocomial, with a more 26 
frequent catheter-related source and an increased rate of C. glabrata infection. Their 27 
mortality remained the same (37% at one month).  28 
 29 
We similarly reported a 30-day mortality of 40% in 2006.2 Since then we have instituted a 30 
number of interventions including in-house identification and susceptibility testing, use of 31 
echinocandins as empirical therapy, and the introduction of an antifungal stewardship (AFS) 32 
team comprised of a consultant microbiologist and antimicrobial pharmacist in July 2013.3 33 
Part of the role of the AFS team included the introduction of a candidaemia care bundle 34 
which involves the clinical review of six elements of care: commencement of an antifungal 35 
agent on the same day as the microscopy result is reported; removal of central venous 36 
catheters (CVC) within four days of candidaemia onset in non-neutropenic patients; sending 37 
repeat blood cultures; performing echocardiography; ophthalmology review; and 38 
subsequent rationalisation of therapy on the same day as susceptibility results become 39 
available. These were chosen in line with the Infectious Diseases Society of America 40 
guidelines on the management of candidaemias.4 We compared the management and 41 
outcomes of patients with candidaemias prior to and after the implementation of the AFS 42 
programme. 43 
 44 
The evaluation was conducted at Cambridge University Hospitals NHS Foundation Trust 45 
(CUH), a large, single-site, tertiary teaching hospital in the East of England with 1,100 beds, 46 
70,000 inpatient admissions and 170,000 total admissions per annum. The hospital offers a 47 
number of specialist services, including solid organ transplantation (multivisceral, liver, renal 48 
and pancreas transplants), haematology/oncology (including stem cell transplantation) and 49 
neurosurgery. 50 
 51 
All patients (adult and paediatric) with first episode of Candida spp. bloodstream infection 52 
during the study period were included in the study. Patients who died prior to blood 53 
cultures becoming positive were excluded from the analysis. The primary team responsible 54 
for patient care routinely received phone advice on management from a clinical 55 
microbiologist following a positive blood culture result. In addition, patients in the post-56 
intervention group were reviewed by the AFS team. Data was obtained retrospectively for 57 
the pre-intervention group and prospectively in the post-intervention group and included 58 
compliance with all six elements of care as outlined earlier, markers of clinical severity at 59 
baseline (Charlson comorbidity index, CCI) and 30-day mortality. Statistical analysis was 60 
performed using the two-tailed Fisher’s exact test for categorical variables and Mann 61 
Whitney U test for continuous variables on IBM SPSS Statistics v20 software programme 62 
(IBM, New York, USA). The study was registered with the CUH audit department and did not 63 
require ethical approval. 64 
 65 
There were 47 candidaemia episodes in 2009-2010 and 33 episodes in 2013-2014 (Table 1). 66 
The proportion of candidaemia due to C. albicans fell from 48% in 2009-10 to 39% in 2013-67 
14 (p=0.34). Three patients with candidaemia from 2009-10 were excluded from further 68 
analysis due to death occurring prior to blood cultures becoming positive. The baseline age 69 
and severity of illness did not differ significantly between the two periods (median CCI 3 in 70 
2009-10 versus 4 in 2013-14; p=0.52). 71 
 72 
The implementation of the AFS programme led to improved compliance with all elements of 73 
the care bundle: initiation of effective treatment on the day of the positive microscopy 74 
result (94% versus 93%; p=1.00), follow up blood cultures (100% versus 93%; p=0.26), timely 75 
removal of CVC (91% versus 65%; p=0.03), ophthalmology review (100% versus 64%; 76 
p<0.01) and echocardiography (100% versus 88%; p=0.06). There was a higher rate of timely 77 
rationalisation of antifungal therapy (83% versus 43%; p=0.02) and a trend towards 78 
improved 30-day mortality (9% versus 27%; p=0.08). Initial clinical review lasted 79 
approximately 10 minutes and follow-up review a further 10 minutes to confirm that all the 80 
actions had been performed. 81 
 82 
The rise in the proportion of non-albicans Candida has been described previously,1 but 83 
whilst they reported a rise in the number of candidaemias over time, we found a (non-84 
significant) fall, similar to that described by Cleveland and colleagues.5 They suggested this 85 
could be due to improved practice in the care of patients with CVC; our institution, along 86 
with other English hospitals has seen a fall in CVC-related bloodstream infections in recent 87 
years.6 88 
 89 
Whilst a number of studies have described individual elements of the care bundle being 90 
associated with improved mortality (e.g. CVC removal and echinocandin use), only three 91 
studies have described care bundles for candidaemia previously. Antworth and colleagues7 92 
describe a single-centre before-after study comparing 37 patients (pre-intervention) with 41 93 
patients (post-intervention) and found improvements in care. Reed and colleagues8 describe 94 
a single-centre before-after study comparing 85 (pre-intervention) and 88 patients (post 95 
intervention). Time to effective therapy was significantly shorter and therapy was 96 
administered to more patients in the post-intervention group (88% versus 99%; p=0.008) 97 
but they found no significant difference in in-hospital mortality (19% versus 30%; p=0.11), 98 
infection-related length of stay or hospital costs during candidaemia. Takesue and 99 
colleagues9 describe a multicentre study involving 608 patients in order to assess if 100 
compliance with the bundle improved mortality. They found a significant difference in 101 
clinical success between patients with and without compliance (92.9% versus 75.8%; 102 
p<0.01). Compliance with the bundles, however, was poor overall and failed to be an 103 
independent factor associated with favourable outcomes. Completion of all elements of the 104 
bundle in our study increased from 29% (12/42) pre-intervention to 87% (27/31) post-105 
intervention (p<0.01). 106 
 107 
We acknowledge that this is a small single centre study but we believe that the 108 
implementation of the new candidaemia care bundle as part of the AFS programme was 109 
effective in improving compliance with standards of patient care, and led to targeted and 110 
more cost effective antifungal therapy and an overall improvement in clinical outcome, with 111 
minimal time (approximately one hour per month) and financial investment. 112 
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Table 1: Comparative descriptive analysis of candidaemia cases in the two study periods 155 
Demographics 2009-2010  
n=44 
2013-2014  
n=33 
p-value  
Age, median (interquartile 
range) 
  Range 
 
64 (47 – 72.5) 
 
15-96 
 
56 (39-75) 
 
0 – 84 
 
0.40 
Male 26 (59%) 15 (46%) 0.26 
Care bundle    
Adequate empirical therapy 41/42* (98%) 32/32** (100%) 0.57 
Effective empirical therapy 
commenced same day as 
positive microscopy 
39/42* (93%) 30/32** (94%) 1.00 
Removal of CVC in non-
neutropenic patients within 4 
days of candidaemia onset 
20/31 (65%) 21/23 (91%) 0.03 
Follow up blood cultures for 
clearance 
41 (93%) 33 (100%) 0.26 
Ophthalmology review 27/42* (64%) 33 (100%) <0.01 
Echocardiography 37/42* (88%) 33 (100%) 0.06 
De-escalation to fluconazole 
*** 
9/21 (43%)  
 
15/18 (83%)  
 
0.02 
All elements of the bundle 
completed 
12/42* (29%) 27/31** (87%) <0.01 
Severity    
Charlson co-morbidity score, 
median (interquartile range) 
3 (2-5)  4 (2-6) 0.52 
Outcome    
Death at 1 month 12 (27%) 3 (9%) 0.08 
Empirical treatment    
Echinocandin  30 (65%) 25 (76%) 0.35 
Fluconazole 5 (10%) 5 (15%) 0.45 
Liposomal amphotericin B 7 (15%) 2 (6%) 0.16 
 156 
CVC: central venous catheter.  157 
*2 patients not treated due to palliation 158 
** missing data  159 
***Excluded 23 patients from 2009-10 and 15 patients from 2013-4 for the following reasons: 160 
fluconazole-resistant isolate, fluconazole allergy, delay in obtaining susceptibility results, fluconazole 161 
used as empirical therapy, patients not treated.   162 
Microbiology  n=47 n=33  
C. albicans 22 (48%) 13 (39%) 0.34 
C. glabrata 17 (37%) 14 (42%) 0.37 
Other Candida spp. 8 (17%)  6 (18%) 0.56 
